1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag

Magle Chemoswed Holding Reports Financial Results For Second Quarter 2023

MAR

Today, on 18 Julyl 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q2 2023.

APR-JUN 2023 KEY INDICATORS

  • Net sales amounted to 38.1 MSEK (35.5).
  • EBITDA equalled 9.5 MSEK (7.7).
  • Operating profit (EBIT) is 6.3 MSEK (4.2)
  • Profit after tax amounted to 4.7 MSEK (3.8)
  • Earnings per share SEK 0,4 (0,4) per share

JAN-JUN 2023 KEY INDICATORS

  • Net sales amounted to 76.7 MSEK (65.7).
  • EBITDA equalled 17.0 MSEK (15.4).
  • Operating profit (EBIT) is 10.6 MSEK (8.8)
  • Profit after tax amounted to 7.6 MSEK (7.9)
  • Earnings per share SEK 0,7 (0,7) per share


“In the second quarter, we expanded our project portfolio, strong clinical data for SmartPAN® was presented to key opinion leaders, and total revenues from our CDMO business and DSM-based products increased by 7.4 percent compared to the corresponding period last year.” says Justin Pierce, CEO of Magle Group.

The full report is available at https://maglegroup.com/financial-reports/

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-07-18 08:30 CEST.

Attachments

Interim Report Q2 2023

Datum 2023-07-18, kl 08:30
Källa MFN
Bifogade filer
Interim Report Q2 2023
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!